BCAX — Bicara Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 2023658 ·
Last close
$9.60
Market Cap
$637.32M
52W High
$30.99
52W Low
$7.87
ADV30
1,816,025
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 0 | — | -75,711,000 | -71,249,000 | 460,642,000 | 82,021,000 | 51,231,000 |
| Jun 2026 | 0 | — | -59,951,000 | -55,436,000 | 512,243,000 | 96,599,000 | 43,475,000 |
| Mar 2026 | 0 | — | -60,242,000 | -56,211,000 | 553,599,000 | 323,462,000 | 39,641,000 |
| Dec 2025 | 0 | — | -41,122,000 | -37,386,000 | 430,994,000 | 96,685,000 | 29,542,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-161,729,000
Investing CF
$-128,044,000
Financing CF
$200,121,000
CapEx
$-1,021,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.47
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-541,862,000
Inventory
—
Receivables
—
ST Investments
$360,325,000
EBIT TTM
$-237,026,000
Pretax Income TTM
$-220,062,000
Interest Exp TTM
—
Analysts
12
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -155,604,000 | -137,950,000 | 430,994,000 | 29,542,000 | 401,452,000 | -106,834,000 |
| Dec 2024 | 0 | -82,389,000 | -67,995,000 | 509,996,000 | 18,121,000 | 491,875,000 | -74,751,000 |
| Dec 2023 | 0 | -39,889,000 | -51,985,000 | 233,982,000 | 382,751,000 | -148,769,000 | -45,628,000 |
| Dec 2022 | 0 | -37,656,000 | -37,845,000 | 6,703,000 | 105,506,000 | -98,803,000 | -32,076,000 |
TTM Snapshot
Revenues TTM
$16,834,000
NetIncome TTM
$-185,363,000
OpCashFlow TTM
—
Assets (Latest)
$512,243,000
Forward EPS
$-3.89
Max Pain — expiry 2027-12-17 (volume-derived — Yahoo OI feed degraded)
max pain strike: $10.00 · spot: $9.38 · call volume: 3 · put volume: 386Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| OLMA | Olema Oncology, Inc. | $632.52M | $7.22 | — |
| SVA | SINOVAC BIOTECH LTD | $642.44M | $6.47 | — |
| GERN | GERON CORP | $644.24M | $1.00 | — |
| DSGN | Design Therapeutics, Inc. | $630.12M | $9.84 | — |
| ALMS | ALUMIS INC. | $628.33M | $4.84 | — |
News headlines (Yahoo Finance, 1h cache)
Bicara Therapeutics (BCAX) Stock Gets Fair Value Trim As Analysts Split On Ficera
2026-11-13 01:13 · Yahoo
Bicara Therapeutics Inc (BCAX) Q3 2026 Earnings Call Highlights: Strong Enrollment Momentum and ...
2026-11-10 11:02 · Yahoo
Bicara (BCAX) Q3 2026 Earnings Call Transcript
2026-11-09 19:43 · Yahoo
Bicara Therapeutics Inc. Common Stock Q3 2026 Earnings Call Summary
2026-11-09 17:55 · Yahoo
What Bicara Therapeutics (BCAX) Said on Its Q3 Earnings Call
2026-11-09 16:15 · Yahoo
Bicara Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business Update
2026-11-09 12:30 · Yahoo
Bicara Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2026-11-04 13:30 · Yahoo
Bicara Therapeutics to Report Third Quarter 2026 Financial Results and Business Updates on November 9, 2026, at 8:30 AM ET
2026-11-02 13:30 · Yahoo
Bicara Therapeutics (BCAX) Stock May Look Overvalued On Book Value
2026-10-10 10:09 · Yahoo
Bicara Therapeutics (BCAX) Q2 2026 Earnings Call Transcript
2026-08-18 15:13 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.